BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: A population-based study in central Italy

Breast Cancer Research and Treatment

Volumn 116, Issue 3, 2009, Pages 577-586

  Ottini, Laura ^a   Rizzolo, Piera ^a   Zanna, Ines ^b   Falchetti, Mario ^a   Masala, Giovanna ^b   Ceccarelli, Ketty ^a   Vezzosi, Vania ^c   Gulino, Alberto ^a   Giannini, Giuseppe ^a   Bianchi, Simonetta ^c   Sera, Francesco ^b   Palli, Domenico ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

BRCA1; BRCA2 Germ line mutations; Clinical pathologic features; Male breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; FAMILY HISTORY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; ITALY; MAJOR CLINICAL STUDY; MALE; MALE BREAST; MUCINOUS CARCINOMA; NUCLEOTIDE SEQUENCE; PAGET NIPPLE DISEASE; PAPILLARY CARCINOMA; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; COLLOID CARCINOMA; ENZYME IMMUNOASSAY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; LUNG CARCINOMA; MIDDLE AGED; MUTATION; PEDIGREE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HAPLOTYPES; HUMANS; IMMUNOENZYME TECHNIQUES; ITALY; MALE; MIDDLE AGED; PEDIGREE;

EID: 70349581484     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0194-z     Document Type: Article

References (35)

1. NCI, SEER (Surveillance Epidemiology and End Results) database 2007
2. Speirs V, Shaaban AM (2008) The rising incidence of male breast cancer. Breast Cancer Res Treat (Epub ahead of print)
3. Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367:595-604. doi:10.1016/S0140-6736(06)68226-3
4. Zanetti R, Gafà L, Pannelli F, Conti E, Rosso S (eds) (2001) Il cancro in Italia 3. I dati dei Registri Tumori. Volume terzo: 1993-1998. Il Pensiero Scientifico Editore, Roma
5. Agrawal A, Ayantunde AA, Rampaul R, Robertson JF (2007) Male breast cancer: a review of clinical management. Breast Cancer Res Treat 103:11-21. doi:10.1007/s10549-006-9356-z
6. Giordano SH (2005) A review of the diagnosis and management of male breast cancer. Oncologist 10:471-479. doi:10.1634/theoncologist.10-7-471
7. Ferla R, Calo V, Cascio S (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6):vi93-vi98. doi: 10.1093/annonc/mdm234
8. Baudi F, Quaresima B, Grandinetti C, Cuda G, Faniello C, Tassone P et al (2001) Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. Hum Mutat 18:163-164. doi:10.1002/humu.1167
9. Pisano M, Cossu A, Persico I, Palmieri G, Angius A, Casu G et al (2000) Identification of a founder BRCA2 mutation in Sardinia. Br J Cancer 82:553-559. doi:10.1054/bjoc.1999.0963
10. Russo A, Calo V, Bruno L, Schiro V, Agnese V, Cascio S et al (2008) Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? Breast Cancer Res Treat (Epub ahead of print)
11. Malacrida S, Agata S, Callegaro M, Casella C, Barana D, Scaini MC et al (2008) BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy. J Clin Oncol 26:26-31. doi:10.1200/JCO.2007.13.2118
12. Tournier I, Paillerets BB, Sobol H, Stoppa-Lyonnet D, Lidereau R, Barrois M et al (2004) Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 64:8143-8147. doi:10.1158/0008-5472.CAN- 04-2467
13. Woodward AM, Davis TA, Silva AG, Kirk JA, Leary JA (2005) kConFab investigators. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. J Med Genet 42:e31. doi:10.1136/jmg.2004.027961
14. Gutierrez-Enriquez S, de La Hoya M, Martinez-Bouzas C, De Abajo AS, Cajal TR, Llort G et al (2006) Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat 103:103-107. doi:10.1007/s10549-006-9376-8
15. Machado PM, Brandao RD, Cavaco BM, Eugenio J, Bento S, Nave M et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027-2034. doi:10.1200/JCO.2006.06.9443
16. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379-1388. doi:10.1001/jama.295.12.1379
17. Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V et al (2008) BRCA1/2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110:161-167. doi:10.1007/s10549-007-9689-2
18. Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R (2007) Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 109:1471-1477. doi:10.1002/cncr.22589
19. Honrado E, Osorio A, Palacios J, Benitez J (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25:5837-5845. doi:10.1038/sj.onc.1209875
20. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB et al (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31:121-128. doi:10.1097/01.pas.0000213351.49767.0f
21. Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A (2003) BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 9(12): 4452-4459
22. Burga AM, Fadare O, Lininger RA, Tavassoli FA (2006) Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch 449:507-512. doi:10.1007/s00428-006-0305-3
23. Evans DG, Bulman M, Young K, Howard E, Bayliss S, Wallace A et al (2008) BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam Cancer 7:113-117. doi:10.1007/s10689-007-9153-9
24. Syrjäkoski K, Kuukasjärvi T, Waltering K, Haraldsson K, Auvinen A, Borg A et al (2004) BRCA2 mutations in 154 finnish male breast cancer patients. Neoplasia 6:541-545. doi:10.1593/neo.04193
25. Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G et al (2003) BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 63:342-347
26. Parmigiani G, Berry DA, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158. doi:10.1086/301670
27. Bianchi S, Palli D, Falchetti M, Saieva C, Masala G, Mancini B et al (2006) ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol 206:702-708. doi:10.1002/jcp.20535
28. Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D (2007) Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 105:169-175. doi:10.1007/s10549-006-9448-9
29. Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF et al (2002) BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4:R2. doi:10.1186/bcr419
30. Chodick G, Struewing JP, Ron E, Rutter JL, Iscovich J (2008) Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999. Eur J Med Genet 51:141-147. doi:10.1016/j.ejmg.2007.11.001
31. Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D et al (2008) Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat (in press). doi:10.1007/s10549-008-0190-3
32. Capalbo C, Buffone A, Vestri A, Ricevuto E, Rinaldi C, Zani M et al (2007) Does the search for large genomic rearrangements impact BRCAPRO carrier prediction? J Clin Oncol 25:2632-2634. doi:10.1200/JCO.2007.11.4330
33. Miolo G, Puppa LD, Santarosa M, De Giacomi C, Veronesi A, Bidoli E et al (2006) Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in North-east of Italy. BMC Cancer 6:156. doi:10.1186/1471-2407-6-156
34. Pich A, Chiusa L, Margarina E (1994) Proliferative activity is a significant prognostic factor in male breast carcinoma. Am J Pathol 145:481-489
35. Muñoz de Toro MM, Maffini MV, Kass L, Luque EH (1998) Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 67:333-339. doi:10.1016/S0960-0760(98)00124-1